Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model.

diabetes complications diabetic retinopathy glibenclamide glyburide retinal edema retinal neuroprotection sulfonylureas

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
17 Jul 2021
Historique:
received: 31 05 2021
revised: 13 07 2021
accepted: 15 07 2021
entrez: 10 8 2021
pubmed: 11 8 2021
medline: 11 8 2021
Statut: epublish

Résumé

Diabetic retinopathy (DR) remains a major cause of vision loss, due to macular edema, retinal ischemia and death of retinal neurons. We previously demonstrated that acute administration of glibenclamide into the vitreous, or given orally at a non-hypoglycemic dose, protected the structure and the function of the retina in three animal models that each mimic aspects of diabetic retinopathy in humans. In this pilot study, we investigated whether one year of chronic oral glibenclamide, in a non-hypoglycemic regimen (Amglidia

Identifiants

pubmed: 34371786
pii: pharmaceutics13071095
doi: 10.3390/pharmaceutics13071095
pmc: PMC8308933
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Agence Nationale de la Recherche
ID : ANR-15-CE18-0032
Organisme : CRO Centre de Recherche d'Ophtalmologie-Tous Unis pour la Vision
ID : 2020
Organisme : Société Francophone du Diabète
ID : 2019
Organisme : Aide aux jeunes diabétiques
ID : 2013;2014

Références

Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):29
pubmed: 32324858
Sci Rep. 2017 Aug 18;7(1):8834
pubmed: 28821742
Invest Ophthalmol Vis Sci. 2004 Mar;45(3):1002-8
pubmed: 14985323
Front Neurol. 2021 Apr 27;12:656520
pubmed: 33986719
Arq Bras Oftalmol. 2021 Jan-Feb;84(1):67-73
pubmed: 33470344
Int Ophthalmol. 2021 May 6;:
pubmed: 33954860
Medicina (Kaunas). 2021 Mar 05;57(3):
pubmed: 33807881
Int J Ophthalmol. 2021 Jan 18;14(1):42-49
pubmed: 33469482
World J Diabetes. 2015 Apr 15;6(3):489-99
pubmed: 25897358
Acta Neurochir Suppl. 2016;121:13-8
pubmed: 26463916
Prog Retin Eye Res. 2008 Jan;27(1):1-44
pubmed: 18042420
Front Pediatr. 2020 Sep 30;8:540718
pubmed: 33102403
Mediators Inflamm. 2017;2017:3578702
pubmed: 28740332
Ophthalmol Ther. 2021 Jun;10(2):245-260
pubmed: 33846958
Am J Pathol. 2011 Aug;179(2):942-53
pubmed: 21712024
Med Sci (Paris). 2003 Aug-Sep;19(8-9):847-53
pubmed: 14593616
Prog Retin Eye Res. 2018 Mar;63:20-68
pubmed: 29126927
Br J Ophthalmol. 2021 Feb;105(2):216-221
pubmed: 32265201
Nat Med. 2006 Apr;12(4):433-40
pubmed: 16550187
Metabolism. 2002 Nov;51(11):1452-7
pubmed: 12404197
BMJ Open. 2016 Jan 13;6(1):e010210
pubmed: 26769791
J Neuroinflammation. 2016 Jun 01;13(1):130
pubmed: 27246103
Biomed Pharmacother. 2020 Dec;132:110811
pubmed: 33069967
Int J Mol Sci. 2015 Mar 04;16(3):4973-84
pubmed: 25749474
Oxid Med Cell Longev. 2019 Apr 7;2019:6734836
pubmed: 31089412
J Stroke Cerebrovasc Dis. 2021 Mar;30(3):105595
pubmed: 33450605
Stroke. 2007 Sep;38(9):2526-30
pubmed: 17673715
Antioxidants (Basel). 2020 Nov 15;9(11):
pubmed: 33203090
J Neurotrauma. 2021 Mar;38(5):628-645
pubmed: 33203303
J Ophthalmol. 2015;2015:757412
pubmed: 25821591
Curr Eye Res. 2020 Aug;45(8):965-974
pubmed: 31902231
Surv Ophthalmol. 1999 Jul-Aug;44(1):53-60
pubmed: 10466588
Transl Vis Sci Technol. 2014 Jun 19;3(3):6
pubmed: 24959388
Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):123-133
pubmed: 30640976
Exp Eye Res. 2021 Jan;202:108384
pubmed: 33285185
J Pharmacol Pharmacother. 2010 Jan;1(1):18-23
pubmed: 21808586
PLoS One. 2016 Aug 25;11(8):e0148855
pubmed: 27560494
PLoS One. 2013 Nov 29;8(11):e81600
pubmed: 24312324
Neuropharmacology. 2020 Jan 1;162:107845
pubmed: 31704276
Neurotherapeutics. 2021 Feb 3;:
pubmed: 33537951
Surg Neurol Int. 2021 Mar 02;12:80
pubmed: 33767884
Cochrane Database Syst Rev. 2020 Nov 17;11:CD005656
pubmed: 33206392
Eur J Pharmacol. 1997 Sep 24;335(2-3):227-34
pubmed: 9369378
Medicine (Baltimore). 2020 Mar;99(10):e19378
pubmed: 32150083
Invest Ophthalmol Vis Sci. 1996 Apr;37(5):898-905
pubmed: 8603874
Transl Res. 2021 Mar;229:83-99
pubmed: 33080394
J Diabetes Res. 2019 Sep 15;2019:8724818
pubmed: 31637263
Exp Eye Res. 2002 May;74(5):615-25
pubmed: 12076083
JAMA Ophthalmol. 2021 Mar 1;139(3):302-309
pubmed: 33475696
Diabetes Care. 2015 Nov;38(11):2033-41
pubmed: 26438614
BMJ Open. 2021 May 10;11(5):e043585
pubmed: 33972335

Auteurs

Marianne Berdugo (M)

Physiopathology of Ocular Diseases: Therapeutic Innovations, Sorbonne University and Universityof Paris, Inserm UMRS 1138, F-75006 Paris, France.

Kimberley Delaunay (K)

Physiopathology of Ocular Diseases: Therapeutic Innovations, Sorbonne University and Universityof Paris, Inserm UMRS 1138, F-75006 Paris, France.

Cécile Lebon (C)

Physiopathology of Ocular Diseases: Therapeutic Innovations, Sorbonne University and Universityof Paris, Inserm UMRS 1138, F-75006 Paris, France.

Marie-Christine Naud (MC)

Physiopathology of Ocular Diseases: Therapeutic Innovations, Sorbonne University and Universityof Paris, Inserm UMRS 1138, F-75006 Paris, France.

Lolita Radet (L)

Physiopathology of Ocular Diseases: Therapeutic Innovations, Sorbonne University and Universityof Paris, Inserm UMRS 1138, F-75006 Paris, France.

Léa Zennaro (L)

Physiopathology of Ocular Diseases: Therapeutic Innovations, Sorbonne University and Universityof Paris, Inserm UMRS 1138, F-75006 Paris, France.

Emilie Picard (E)

Physiopathology of Ocular Diseases: Therapeutic Innovations, Sorbonne University and Universityof Paris, Inserm UMRS 1138, F-75006 Paris, France.

Alejandra Daruich (A)

Physiopathology of Ocular Diseases: Therapeutic Innovations, Sorbonne University and Universityof Paris, Inserm UMRS 1138, F-75006 Paris, France.
Department of Ophthalmology, AP-HP Hospital University Necker-Sick Children, F-75015 Paris, France.

Jacques Beltrand (J)

Department of Paediatric Endocrinology, Gynecology and Diabetology, AP-HP Hospital University Necker-Sick Children, F-75015 Paris, France.
Faculté de Santé, University of Paris, F-75006 Paris, France.
Institut Cochin, InsermU1016, F-75005 Paris, France.

Elsa Kermorvant-Duchemin (E)

Physiopathology of Ocular Diseases: Therapeutic Innovations, Sorbonne University and Universityof Paris, Inserm UMRS 1138, F-75006 Paris, France.
Neonatal and Intensive Care Unit, AP-HP Hospital University Necker-Sick Children, F-75015 Paris, France.

Michel Polak (M)

Department of Paediatric Endocrinology, Gynecology and Diabetology, AP-HP Hospital University Necker-Sick Children, F-75015 Paris, France.
Faculté de Santé, University of Paris, F-75006 Paris, France.
Institut Cochin, InsermU1016, F-75005 Paris, France.
Institute Imagine, InsermU1163, F-75015 Paris, France.

Patricia Crisanti (P)

Physiopathology of Ocular Diseases: Therapeutic Innovations, Sorbonne University and Universityof Paris, Inserm UMRS 1138, F-75006 Paris, France.

Francine F Behar-Cohen (FF)

Physiopathology of Ocular Diseases: Therapeutic Innovations, Sorbonne University and Universityof Paris, Inserm UMRS 1138, F-75006 Paris, France.
Ophthalmology, AP-HP Hospital Cochin, F-75005 Paris, France.

Classifications MeSH